CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the effects of CBM588 in combination with standard therapies,
nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other
places in the body (advanced/metastatic). The digestive microbiome may have an effect on how
patients respond to treatment, and previous research shows that a specific bacteria found in
the gut (Bifidobacterium) may predispose participants to a better response to standard
therapies. CBM588 is a strain of bacteria that can restore species of Bifidobacterium to the
microbiome. The primary aim of this study is to determine how CBM588 changes the microbiome
of patients with metastatic renal cell carcinoma. Immunotherapy with monoclonal antibodies,
such as nivolumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. cabozantinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving CBM588, nivolumab, and
cabozantinib may kill more tumor cells.